Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study

被引：1
|
作者：
le Coutre, Philipp D. [1 ]
Turkina, Anna [2 ]
Kim, Dong-Wook [3 ]
Ceglarek, Bernadeta [4 ]
Alimena, Giuliana [5 ]
Al-Ali, Haifa Kathrin [6 ]
Shen, Zhixiang [7 ]
Jootar, Saengsuree [8 ]
Smith, Graeme [9 ]
De Souza, Carmino Antonio [10 ,11 ]
Dorlhiac-Llacer, Pedro Enrique [12 ]
Rizzieri, David A. [13 ]
Szczudlo, Tomasz [14 ]
Berton, Myriam [15 ]
Wang, Jim [16 ]
Wang, Si-Tien [17 ]
Nicolini, Franck Emmanuel [18 ]
机构：
[1] Humboldt Univ, Charite, Dept Hematol & Oncol, Berlin, Germany
[2] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia
[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[4] Inst Hematol & Transfufzjol, Warsaw, Poland
[5] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
[6] Univ Leipzig, Dept Hematol Oncol, Leipzig, Germany
[7] Shanghai Ruijin Hosp, Shanghai, Peoples R China
[8] Mahidol Univ, BMT Program, Ramathibodi Hosp, Bangkok 10700, Thailand
[9] Dept Haematol, Leeds, W Yorkshire, England
[10] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Sao Paulo, Brazil
[11] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil
[12] FMUSP, Hosp Clin, Sao Paulo, Brazil
[13] Duke Univ, Med Ctr, Durham, NC USA
[14] Novartis Pharmaceut, Florham Pk, NJ USA
[15] Novartis Pharmaceut, Basel, Switzerland
[16] Novartis Pharmaceut, E Hanover, NJ USA
[17] Anal Grp Inc, Boston, MA USA
[18] Hop Edouard Herriot, Lyon, France
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1272 / 1273
页数：2
相关论文
共 50 条
  • [11] ENACT (Expanding Nilotinib Access in Clinical Trials) study in adult patients (pts) with Imatinib-resistant or - intolerant Chronic Myeloid Leukemia (CML): Subgroup analysis of Pts from Germany, Austria and Switzerland (DACH)
    Al-Ali, H. K.
    le Coutre, P.
    Duyster, J.
    Linkesch, W.
    Wolf, D.
    Schanz, U.
    Baerlocher, G. M.
    Wackwitz, B.
    Heim, D.
    ONKOLOGIE, 2011, 34 : 267 - 267
  • [12] Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study
    Nicolini, Franck Emmanuel
    Etienne, Gabriel
    Bordessoule, Dominique
    Caillot, Denis
    Belanger, Coralie
    Cayuela, Jean-Michel
    Charbonnier, Aude
    Coiteux, Valerie
    Guerci-Bresler, Agnes
    Dubruille, Viviane
    Lamy, Thierry
    Huguet, Francoise
    Rousselot, Philippe
    Tulliez, Michel
    Cahn, Jean-Yves
    Gardembas-Pain, Martine
    Legros, Laurence
    Maloisel, Frederic
    Rea, Delphine
    Johnson-Ansah, Hyacinthe
    Lenain, Pascal
    Delmer, Alain
    Berger, Marc
    Szczudlo, Tomasz
    Wang, Jim
    Duh, Mei Sheng
    Guilhot, Francois
    BLOOD, 2009, 114 (22) : 1276 - 1277
  • [13] Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
    Giles, Francis J.
    Yin, Ophelia
    Chia, Yen Lin
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 390 - 390
  • [14] Safety, and efficacy of nilotinib dose escalation 600mg BID in patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP)
    Hochhaus, Andreas
    Giles, Francis J.
    le Coutre, Philipp
    Baccarani, Michele
    Gattertnann, Norbert
    Bhalla, Kapil N.
    Alimena, Giuliana
    Ossenkoppele, Gert
    Nicolini, Franck
    Litzow, Mark R.
    Bbatia, Ravi
    Cervantes, Francisco
    Wang, Jim
    Woodman, Richard
    Cortes, Jorge
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 314A - 315A
  • [15] Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
    Giles, F. J.
    Kantarjian, H. M.
    le Coutre, P. D.
    Baccarani, M.
    Mahon, F-X
    Blakesley, R. E.
    Gallagher, N. J.
    Gillis, K.
    Goldberg, S. L.
    Larson, R. A.
    Hochhaus, A.
    Ottmann, O. G.
    LEUKEMIA, 2012, 26 (05) : 959 - 962
  • [16] Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
    F J Giles
    H M Kantarjian
    P D le Coutre
    M Baccarani
    F-X Mahon
    R E Blakesley
    N J Gallagher
    K Gillis
    S L Goldberg
    R A Larson
    A Hochhaus
    O G Ottmann
    Leukemia, 2012, 26 : 959 - 962
  • [17] NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Koren-Michowitz, M. K. M.
    Le Coutre, P.
    Duyster, J.
    Scheid, C.
    Rowe, J. M.
    Goldschmidt, N.
    Ribakovsky, E.
    Nagler, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 222 - 223
  • [18] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
    Lipton, Jeffrey H.
    le Coutre, Philipp D.
    Wang, Jim
    Yang, Mindy
    Szczudlo, Tomasz
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [19] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
    Ottmann, O. G.
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Kindler, T.
    Duyster, J.
    Al-Ali, H.
    Lipton, J.
    Wang, J.
    Yang, M.
    Szczudlo, T.
    Giles, F.
    ONKOLOGIE, 2010, 33 : 138 - 138
  • [20] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345